Spots Global Cancer Trial Database for A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
Study ID: NCT06196203
Conditions
Study Description
Brief Summary: This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
American Oncology Partners, PA (The Center for Cancer and Blood Disorders-Bethesda), Bethesda, Maryland, United States
Gabrail Cancer Center, Canton, Ohio, United States
Institute of hematolongy&blood diseases hospital, chinese academy of medical sciences&peking union medical college, Tianjin, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
